Growth inhibition of human gastric adenocarcinoma cells in vitro by STO-609 is independent of calcium/calmodulin-dependent protein kinase kinase-beta and adenosine monophosphate-activated protein kinase.Adenosine monophosphate (AMP)-activated protein kinase is a recently identified downstream target of calcium/calmodulin-dependent protein kinase kinase-beta, and is involved in the regulation of cell metabolism and cell proliferation.  STO-609 is a selective antagonist of calcium/calmodulin-dependent protein kinase kinase-beta.  In the present study, we found that STO-609 suppressed AMP-activated protein kinase activity, reduced expression of Akt and ERK, and increased cell apoptosis in SNU-1 and N87 cells but not normal gastric epithelial cells (CCL-241).  Interestingly, we found such effects of STO-609 on gastric cancer cells were not affected after the knock-down of CaMKK-β and AMPK.  In conclusion, STO-609 is an effective cytotoxic agent for gastric adenocarcinoma in vivo.
STO-609
Growth inhibition of human gastric adenocarcinoma cells in vitro by STO-609 is independent of calcium/calmodulin-dependent protein kinase kinase-beta and adenosine monophosphate-activated protein kinase.Adenosine monophosphate (AMP)-activated protein kinase is a recently identified downstream target of calcium/calmodulin-dependent protein kinase kinase-beta, and is involved in the regulation of cell metabolism and cell proliferation.  STO-609 is a selective antagonist of calcium/calmodulin-dependent protein kinase kinase-beta.  In the present study, we found that STO-609 suppressed AMP-activated protein kinase activity, reduced expression of Akt and ERK, and increased cell apoptosis in SNU-1 and N87 cells but not normal gastric epithelial cells (CCL-241).  Interestingly, we found such effects of STO-609 on gastric cancer cells were not affected after the knock-down of CaMKK-β and AMPK.  In conclusion, STO-609 is an effective cytotoxic agent for gastric adenocarcinoma in vivo.
STO-609
In the present study, we found that STO-609 suppressed AMP-activated protein kinase activity, reduced expression of Akt and ERK, and increased cell apoptosis in SNU-1 and N87 cells but not normal gastric epithelial cells (CCL-241). 
AMP-activated protein kinase
Interestingly, we found such effects of STO-609 on gastric cancer cells were not affected after the knock-down of CaMKK-β and AMPK. 
CaMKK-β
In the present study, we found that STO-609 suppressed AMP-activated protein kinase activity, reduced expression of Akt and ERK, and increased cell apoptosis in SNU-1 and N87 cells but not normal gastric epithelial cells (CCL-241). 
AMP-activated protein kinase